Abstract Library

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#3920 Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary

Introduction: The introduction of peptide receptor radionuclide therapy (PRRT) to the Philippines has allowed for novel approaches in the management of neuroendocrine tumors (NETs).

Conference:

Presenting Author: Chianpian C

Authors: Chianpian C, Bautista-Peñalosa P, Santos C, Bandong I,

Keywords: peptide receptor radionuclide therapy, metastatic pancreatic neuroendocrine tumor, Ga-68 DOTATATE, Lu-177 DOTATATE, Philippines,

#3843 VIPoma presenting as chronic diarrhea in a 30-year-old Filipino female

Introduction: Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. They can secrete a variety of peptide hormones including insulin, gastrin, glucagon, and vasoactive intestinal peptide. Secretory tumors such as vasoactive intestinal polypeptides are rare neuroendocrine pancreatic neoplasms characterized by watery diarrhea, hypokalemia, and hypochlorhydria.

Conference:

Presenting Author: Edejer P

Authors: Edejer P, Mendoza R, Pascasio C, Lin T, Cornelio G,

Keywords: Pancreatic NET, Octreotide, DOTATATE, diarrhea,

#3646 Thymic neuroendocrine neoplasms – Data from the Czech Neuroendocrine Tumor Registry 2008 – 2022

Introduction: Thymic neuroendocrine neoplasms are very rare, their incidence is only 3% of all NENs a 5% of thymic tumors. On ENETS 2022 Sarah Fodil—Cherif et alt. presented data of 74 patients with thymic NETs from retrospective French study (1988-2020) and their analysis.

Conference:

Presenting Author:

Authors: Sedlackova E, Barkmanova J, Linke Z, Karpianusova T,

Keywords: thymic neoplasms, neuroendocrine tumor,

#3576 Patterns of family history of cancer and associated risk of developing neuroendocrine tumors: A cross-sectional study

Introduction: Except for known hereditary syndromes (mostly, multiple endocrine neoplasia type I and von Hippel Lindau), familial clustering of cancers in patients (pts) with neuroendocrine neoplasms (NEN) is scarcely reported.

Conference:

Presenting Author: Viapiana P

Authors: Viapiana P, Dias C, Cruz Formiga M, Simões Riechelmann R,

Keywords: neuroendocrine tumor, family history,